The Role of 11C-Methionine PET Imaging for the Evaluation of Lymphomas: A Systematic Review

Overview

Journal Hematol Rep

Publisher MDPI

Date 2024 Dec 27

PMID 39728002

Authors

Francesco Dondi

Maria Gazzilli

Gian Luca Vigano

Antonio Rosario Pisani

Cristina Ferrari

Giuseppe Rubini

Francesco Bertagna

Affiliations

Soon will be listed here.

Abstract

: In the last years, different evidence has underlined a possible role for [11C]-methionine ([11C]MET) positron emission tomography (PET) imaging for the evaluation of lymphomas. The aim of this paper was, therefore, to review the available scientific literature focusing on this topic. : A wide literature search of the PubMed/MEDLINE, Scopus and Cochrane Library databases was conducted in order to find relevant published articles investigating the role of [11C]MET in the assessment of lymphomas. : Eighteen studies were included in the systematic review and the main fields of application of this imaging modality were the evaluation of disease, therapy response assessment, prognostic evaluation and differential diagnosis with other pathological conditions. : Even with heterogeneous evidence, a possible role for [11C]MET PET imaging in the assessment of lymphomas affecting both the whole body and the central nervous system was underlined. When compared to [18F]fluorodesoxyglucose ([18F]FDG) imaging, in general, similar results have been reported between the two modalities in these settings.

References

Lindholm P, Lapela M, Joensuu H, NORDMAN E . Imaging of head and neck tumors with positron emission tomography and [11C]methionine. Int J Radiat Oncol Biol Phys. 1994; 30(5):1195-9. DOI: 10.1016/0360-3016(94)90328-x. View

Xu W, Gao L, Shao A, Zheng J, Zhang J . The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence. Oncotarget. 2017; 8(53):91030-91039. PMC: 5710903. DOI: 10.18632/oncotarget.19024. View

Zirakchian Zadeh M . Clinical Application of F-FDG-PET Quantification in Hematological Malignancies: Emphasizing Multiple Myeloma, Lymphoma and Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2023; 23(11):800-814. DOI: 10.1016/j.clml.2023.07.008. View

Ruotsalainen U, Nagren K, Teras M, Joensuu H . Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med. 1991; 32(6):1211-8. View

Buck A, Bommer M, Juweid M, Glatting G, Stilgenbauer S, Mottaghy F . First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine. J Nucl Med. 2008; 49(11):1756-62. DOI: 10.2967/jnumed.108.055335. View

Sutinen E, Jyrkkio S, Varpula M, Lindholm P, Gronroos T, Lehikoinen P . Nodal staging of lymphoma with whole-body PET: comparison of. J Nucl Med. 2001; 41(12):1980-8. View

Ogawa T, Kanno I, Hatazawa J, Inugami A, Fujita H, Shimosegawa E . Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. Radiographics. 1994; 14(1):101-10. DOI: 10.1148/radiographics.14.1.8128041. View

Wheatley D . On the problem of linear incorporation of amino acids into cell protein. Experientia. 1982; 38(7):818-20. DOI: 10.1007/BF01972291. View

Barrington S, George Mikhaeel N, Kostakoglu L, Meignan M, Hutchings M, Mueller S . Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014; 32(27):3048-58. PMC: 5015423. DOI: 10.1200/JCO.2013.53.5229. View

10.

Norikane T, Mitamura K, Yamamoto Y, Manabe Y, Murao M, Arai-Okuda H . Comparative evaluation of C-methionine and F-fluorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma. J Neurooncol. 2023; 166(1):195-201. DOI: 10.1007/s11060-023-04534-w. View

11.

Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B . Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med. 1995; 36(10):1790-6. View

12.

Rizzo A, Racca M, DallArmellina S, Rescigno P, Banna G, Albano D . The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers (Basel). 2023; 15(2). PMC: 9857064. DOI: 10.3390/cancers15020355. View

13.

Sammartino A, Falco R, Drera A, Dondi F, Bellini P, Bertagna F . "Vascular inflammation and cardiovascular disease: review about the role of PET imaging". Int J Cardiovasc Imaging. 2022; 39(2):433-440. PMC: 9870832. DOI: 10.1007/s10554-022-02730-9. View

14.

Dondi F, Albano D, Bellini P, Volpi G, Giubbini R, Bertagna F . 18F-fluorodeoxyglucose PET and PET/computed tomography for the evaluation of immunoglobulin G4-related disease: a systematic review. Nucl Med Commun. 2022; 43(6):638-645. DOI: 10.1097/MNM.0000000000001566. View

15.

Dondi F, Lazzarato A, Gorica J, Guglielmo P, Borgia F, Filice R . PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score. Life (Basel). 2023; 13(3). PMC: 10057339. DOI: 10.3390/life13030611. View

16.

Stern P, Wallace C, Hoffman R . Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol. 1984; 119(1):29-34. DOI: 10.1002/jcp.1041190106. View

17.

Chauvie S, Castellino A, Bergesio F, De Maggi A, Durmo R . Lymphoma: The Added Value of Radiomics, Volumes and Global Disease Assessment. PET Clin. 2024; 19(4):561-568. DOI: 10.1016/j.cpet.2024.05.009. View

18.

Ohmura K, Ikegame Y, Yano H, Shinoda J, Iwama T . Methionine-PET to differentiate between brain lesions appearing similar on conventional CT/MRI scans. J Neuroimaging. 2023; 33(5):837-844. DOI: 10.1111/jon.13126. View

19.

Nomura Y, Asano Y, Shinoda J, Yano H, Ikegame Y, Kawasaki T . Characteristics of time-activity curves obtained from dynamic C-methionine PET in common primary brain tumors. J Neurooncol. 2018; 138(3):649-658. DOI: 10.1007/s11060-018-2834-4. View

20.

Nakajima R, Kimura K, Abe K, Sakai S . C-methionine PET/CT findings in benign brain disease. Jpn J Radiol. 2017; 35(6):279-288. DOI: 10.1007/s11604-017-0638-7. View